Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis
Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis
Active, not recruiting · NCT05122559 · Registry updated 2026-03-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis | CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic progressive multiple sclerosis, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Active, not recruiting | Phase 2 | 2026-03-11 | NCT05122559 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Emmanuelle Waubant, MD PhD | 1 |
| United States Department of Defense | 319 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of California, San Francisco | San Francisco | United States | 72 |